オプションチェーンは、Rockwell Medicalの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Rockwell Medicalの市場センチメントを評価します。.

Rockwell Medical (NASDAQ:RMTI) 株価情報, オプションチェーン

Rockwell Medical

Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.

Rockwell Medical Inc

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and maintains $7 price target.

News

Price Target

Reiteration

Analyst Ratings

RMTI

HC Wainwright & Co. Reiterates Buy on Rockwell Medical, Maintains $7 Price Target

WIIM

Rockwell Medical shares are trading higher after the company announced expectations for $10 million in FY25 net sales and entered a purchase agreement with a provider of dialysis products and services.

Rockwell Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares are trading higher premarket on Tuesday after it entered into a product purchase agreement with a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42525272/rockwell-medical-enters-into-a-multi-year-product-purchase-agreement-with-the-worlds-leading-provi" rel="noreferrer noopener">provider of dialysis products and services</a>.
As per the three-year agreement, Rockwell Medical will supply its SteriLyte liquid bicarbonate product to the customer, with an option to renew it for two additional one-year terms.
The agreement is expected to generate over $10 million in net sales in the first year, a portion of which was not included in Rockwell Medical&#8217;s previously announced revenue estimates for 2025, with incremental price increases in subsequent years.
Last week, the company announced the promotion of Jesse Neri to the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42456143/rockwell-medical-promotes-jesse-neri-to-chief-financial-officer" rel="noreferrer noopener">post of Chief Financial Officer</a>.
This month, Rockwell Medical disclosed a partnership with HydroCare in which HydroCare will purchase and install Rockwell&#8217;s DAMX45 dry acid concentrate <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42334338/rockwell-medical-partners-with-hydrocare-to-distribute-and-install-its-dry-acid-concentrate-mix-sy" rel="noreferrer noopener">mix system in dialysis water rooms</a>.
This installation is expected to drive new sales for Rockwell&#8217;s dry acid hemodialysis concentrates.
Also, last month, the company inked a distribution deal with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42057509/rockwell-medical-expands-distribution-in-the-philippines" rel="noreferrer noopener">Nephro Group Dialysis Centers</a>.
Price Action: RMTI shares are up 14.4% at $2.29 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42526136" target="_blank" rel="noreferrer noopener">Asia Mostly Lower, Europe Markets Up As Dollar Strengthens Ahead Of Fed Rate Decision &#8211; Global Markets Today While US Slept</a></li>
</ul>
Image via Shutterstock.

Equities

Contracts

Small Cap

Movers

Rockwell Medical Scores Multi-Year Dialysis Deal; Stock Jumps

Under the terms of the Agreement, Rockwell Medical will supply the Customer with the Company's liquid bicarbonate hemodialysis concentrates product, SteriLyte.&nbsp;
The Agreement will remain in effect for three years with the option to renew for two additional one-year periods and is expected to generate upwards of $10 million in net sales for the Company in the first year, a portion of which was not included in Rockwell Medical's previously disclosed revenue estimates for 2025, with incremental price increases each subsequent year.

Rockwell Medical Enters Product Purchase Agreement With AProvider Of Dialysis Products And Services; Partnership Expected To Generate Upwards Of $10M In Net Sales For Company In 2025

Management

Rockwell Medical Promotes Jesse Neri To CFO

Rockwell anticipates that with these new mixer installations through HydroCare, the Company will also generate new sales related to its dry acid hemodialysis concentrates. Rockwell Medical's DAMX45 dry acid concentrate mix system is 510(k) approved to be used exclusively with the Company's CitraPure and Dri-Sate dry acid concentrate powders.&nbsp;

Health Care

General

Rockwell Medical Has Partnered With Hydrocare To Purchase And Install The Company's Dry Acid Concentrate Mix System In Dialysis Water Rooms

Ratings for Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $7.5, a high estimate of $9.00, and a low estimate of $5.00. This current average has decreased by 16.67% from the previous average price target of $9.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1732543258_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Rockwell Medical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Brandon Folkes</td>
<td>Rodman &amp; Renshaw</td>
<td>Announces</td>
<td>Buy</td>
<td>$5.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Rockwell Medical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rockwell Medical compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Rockwell Medical's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Rockwell Medical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RMTI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Rockwell Medical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Rockwell Medical</h2>
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
<h3>Key Indicators: Rockwell Medical's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Rockwell Medical's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 19.12%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 5.88%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Rockwell Medical's ROE excels beyond industry benchmarks, reaching 6.32%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Rockwell Medical's ROA excels beyond industry benchmarks, reaching 3.02%. This signifies efficient management of assets and strong financial health.
Debt Management: Rockwell Medical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.49.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Rockwell Medical Stock

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and lowers the price target from $9 to $7.

HC Wainwright & Co. Maintains Buy on Rockwell Medical, Lowers Price Target to $7

Under the terms of the agreement, Rockwell Medical will be the exclusive supplier of all dry hemodialysis concentrates products, including its CitraPure Acid and RenalPure Bicarbonate, to Nephro Group.

Rockwell Medical Enters Distribution Agreement With Nephro Group Dialysis Centers

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Rodman &amp; Renshaw analyst Brandon Folkes initiated coverage on Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) with a Buy rating and announced a price target of $8. Adial Pharmaceuticals shares closed at $0.9910 on Wednesday. See how other analysts view this stock.</li>
<li>Truist Securities analyst Keith Hughes initiated coverage on Carlisle Companies Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) with a Hold rating and announced a price target of $460. Carlisle shares closed at $454.83 on Wednesday. <a href="https://www.benzinga.com/quote/CSL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rodman &amp; Renshaw analyst Brandon Folkes initiated coverage on Achieve Life Sciences, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) with a Buy rating and announced a price target of $12. Achieve Life Sciences shares closed at $4.53 on Wednesday. See how other analysts view this stock.</li>
<li>Oppenheimer analyst Ian Zaffino initiated coverage on Turning Point Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) with an Outperform rating and announced a price target of $65. Turning Point Brands shares closed at $55.00 on Wednesday. <a href="https://www.benzinga.com/quote/TPB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rodman &amp; Renshaw analyst Brandon Folkes initiated coverage on Rockwell Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy rating and announced a price target of $5. Rockwell Medical shares closed at $2.63 on Wednesday. <a href="https://www.benzinga.com/quote/RMTI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TPB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14075258/image-152-1024x544.png" alt="" class="wp-image-647827" style="width:811px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14075258/image-152-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14075258/image-152-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14075258/image-152-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14075258/image-152.png 1217w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41962884/us-stocks-settle-mixed-following-inflation-data-investor-sentiment-improves-but-fear-index-remains-in-greed-zone">US Stocks Settle Mixed Following Inflation Data: Investor Sentiment Improves, But Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Initiation

Pre-Market Outlook

Trading Ideas

ACHV

ADIL

This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Rodman &amp; Renshaw analyst Brandon Folkes initiates coverage on Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy rating and announces Price Target of $5.

Rodman & Renshaw Initiates Coverage On Rockwell Medical with Buy Rating, Announces Price Target of $5

Rockwell Medical Files For Stock Offering Of Up To $25M

<h3>Gainers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock rose 61.6% to $0.21 during Tuesday's pre-market session. The company's market cap stands at $2.5 million. As per the news, the Q3 earnings report came out today. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares increased by 46.12% to $0.29. The market value of their outstanding shares is at $43.0 million. </li>
<li>Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) shares increased by 28.75% to $6.85. The market value of their outstanding shares is at $255.3 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLDP#NASDAQ">CCLDP</a>) shares rose 28.17% to $15.97. </li>
<li>Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares rose 27.56% to $2.08. The company's market cap stands at $426.1 million. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) shares moved upwards by 22.6% to $3.2. The market value of their outstanding shares is at $51.8 million. As per the press release, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) stock decreased by 40.2% to $1.1 during Tuesday's pre-market session. The market value of their outstanding shares is at $166.8 million. As per the press release, Q3 earnings came out today. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) stock decreased by 31.36% to $49.1. The company's market cap stands at $728.0 million. </li>
<li>Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) shares declined by 27.28% to $0.8. The market value of their outstanding shares is at $24.2 million. The company's, Q3 earnings came out today. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares decreased by 25.81% to $3.45. The market value of their outstanding shares is at $107.0 million. The company's, Q3 earnings came out today. </li>
<li>Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) stock fell 25.3% to $16.27. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares declined by 18.4% to $0.82. The market value of their outstanding shares is at $116.1 million. As per the press release, Q3 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CCLD

CCLDP

CERO

HRTX

LGMK

NGNE

NVRO

SNDX

STIM

TSHA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Rockwell Medical shares are trading lower. The company reported Q3 financial results.

Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.01 by 800 percent. This is a 325 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $28.32 million which beat the analyst consensus estimate of $26.50 million by 6.86 percent. This is a 19.12 percent increase over sales of $23.77 million the same period last year.

Earnings

Rockwell Medical Q3 2024 Adj EPS $0.09 Beats $0.01 Estimate, Sales $28.32M Beat $26.50M Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) will release its quarterly earnings report on Tuesday, 2024-11-12. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Rockwell Medical to report an earnings per share (EPS) of $0.01.
The market awaits Rockwell Medical's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.08, which was followed by a 1.4% increase in the share price the next day.
Here's a look at Rockwell Medical's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.03</td>
<td>-0.04</td>
<td>-0.07</td>
<td>-0.10</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.05</td>
<td>-0.02</td>
<td>0.02</td>
<td>-0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>1.0%</td>
<td>12.0%</td>
<td>13.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731351711_0.png" alt="eps graph" />
<h3>Rockwell Medical Share Price Analysis</h3>
Shares of Rockwell Medical were trading at $4.43 as of November 08. Over the last 52-week period, shares are up 140.73%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Rockwell Medical</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Rockwell Medical.
With 2 analyst ratings, Rockwell Medical has a consensus rating of Buy. The average one-year price target is $9.0, indicating a potential 103.16% upside.
<h3>Peer Ratings Comparison</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of TELA Bio, Cerus and OrthoPediatrics, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, TELA Bio is favoring an Buy trajectory, with an average 1-year price target of $9.5, suggesting a potential 114.45% upside.</li>
<li>As per analysts' assessments, Cerus is favoring an Buy trajectory, with an average 1-year price target of $3.0, suggesting a potential 32.28% downside.</li>
<li>As per analysts' assessments, OrthoPediatrics is favoring an Buy trajectory, with an average 1-year price target of $39.67, suggesting a potential 795.49% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
Within the peer analysis summary, vital metrics for TELA Bio, Cerus and OrthoPediatrics are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rockwell Medical</td>
<td>Buy</td>
<td>42.88%</td>
<td>$4.55M</td>
<td>1.55%</td>
</tr>
<tr>
<td>TELA Bio</td>
<td>Buy</td>
<td>11.02%</td>
<td>$11.07M</td>
<td>-146.05%</td>
</tr>
<tr>
<td>Cerus</td>
<td>Buy</td>
<td>15.70%</td>
<td>$26.20M</td>
<td>-5.70%</td>
</tr>
<tr>
<td>OrthoPediatrics</td>
<td>Buy</td>
<td>36.53%</td>
<td>$40.06M</td>
<td>-2.13%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Rockwell Medical ranks at the bottom for Revenue Growth among its peers. It is at the top for Gross Profit. For Return on Equity, it is in the middle compared to its peers.
<h3>About Rockwell Medical</h3>
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
<h3>Key Indicators: Rockwell Medical's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Rockwell Medical's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 42.88%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 1.33%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Rockwell Medical's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.55%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Rockwell Medical's ROA excels beyond industry benchmarks, reaching 0.66%. This signifies efficient management of assets and strong financial health.
Debt Management: Rockwell Medical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.61.
<a href="https://www.benzinga.com/quote/RMTI/earnings">To track all earnings releases for Rockwell Medical visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Rockwell Medical's Earnings

DaVita, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>) has witnessed strong momentum year to date, with its shares up 47.3% compared with the&nbsp;industry&#39;s&nbsp;growth of 14.8%. The S&amp;P 500 composite has risen 19.5% in the same period.
DaVita,&nbsp;carrying a Zacks Rank #2 (Buy) at present, is witnessing an upward trend in its stock price, prompted by the company&#39;s business model. The optimism, led by a solid second-quarter 2024 performance and the acquisition of dialysis centers, is expected to contribute further.
DaVita is a leading provider of dialysis services in the United States to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services, primarily in dialysis centers and contracted hospitals across the country. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/39/80935.jpg?v=255633029" />
Image Source: Zacks Investment Research
<h2>Catalysts Driving DaVita&#39;s Growth</h2>
The rally in the company&#39;s share price can be attributed to the strength of its dialysis and related lab services. The optimism led by a solid second-quarter 2024 performance and robust business potential are expected to contribute further.
DaVita is experiencing significant growth driven by its patient-centric care approach, leveraging its kidney care services platform to offer a wide range of treatment models and modalities. The increasing prevalence of value-based partnerships in kidney health enables nephrologists, physicians, and transplant programs to collaborate more effectively, enhancing the understanding of individual patient needs and facilitating improved care coordination and early interventions.
A key element of DaVita&#39;s growth strategy is the acquisition of dialysis centers and related businesses, as evident from the recent extension of its pilot phase for a supply and collaboration agreement with Nuwellis. Upon completion of this phase, which ends on Aug. 31, 2024, DaVita may extend the agreement for the ongoing provision of inpatient and outpatient ultrafiltration services for up to 10 years.
The company&#39;s global market share is also on the rise, with recent agreements to expand operations into Brazil, Colombia, Chile and Ecuador.
In the second quarter of 2024, DaVita reported results that exceeded expectations, showcasing a positive trend in both revenue streams and patient services. The sequential increase in daily United States dialysis treatments and the opening of new centers, along with acquisitions overseas, indicates a strong growth trajectory.
Furthermore, DaVita has raised its earnings projections for fiscal 2024, now forecasting adjusted EPS in the range of $9.25 to $10.05, up from the prior range of $9 to $9.80, which is likely to attract further interest from investors.
<h2>Risk Factor</h2>
DaVita faces a risk of reduced profitability if patients shift from commercial insurance to government programs, as government reimbursement rates are significantly lower. This shift could be triggered by rising unemployment, impacting DaVita&#39;s revenues and profit margins.
<h2>A Look at Estimates</h2>
The Zacks Consensus Estimate for DaVita&#39;s 2024 and 2025 bottom line projects an 18% and 14.4% year-over-year improvement, respectively, to earnings of $9.99 and $11.42 per share.
In the past 30 days, the Zacks Consensus Estimate for the company&#39;s 2024 earnings has remained constant at $9.99 per share.
Revenues for 2024 and 2025 are anticipated to rise 5.4% and 4%, respectively, to $12.8 billion and $13.3 billion on a year-over-year basis.
<div class="chart_embed">
<h3>DaVita Inc. Price</h3>
<img alt="DaVita Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/2b/1728478167.png" style="height:251px; width:544px" title="" />
DaVita Inc. price | DaVita Inc. Quote
</div>
<h2>Other Key Picks</h2>
Some other top-ranked stocks in the broader medical space are Rockwell Medical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmti#NASDAQ">RMTI</a>), Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>)&nbsp;and RadNet (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>). While Rockwell Medical carries a Zacks Rank #1 (Strong Buy), Quest Diagnostics&nbsp;and RadNet carry a Zacks Rank #2 each at present.
Rockwell Medical&nbsp;earnings surpassed estimates in each of the trailing four quarters, with the average being 87.9%.
RMTI&#39;s shares have gained 79.7% compared with the industry&#39;s 10.7% growth year to date.
Quest Diagnostics&nbsp;has an estimated long-term growth rate of 6.8%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average being 3.3%.
Quest Diagnostics&nbsp;has gained 7.9% compared with the industry&#39;s 14.9% growth year to date.
RadNet&#39;s&nbsp;earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 98.2%.
RDNT&#39;s shares have gained 93.7% year to date compared with the industry&#39;s&nbsp;14.8% growth.
<a href="https://www.zacks.com/stock/news/2348406/davita-stock-gains-47-3-year-to-date-what-s-behind-the-rally?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2348406">To read this article on Zacks.com click here.</a>

Earnings Beats

Large Cap

Mid Cap

Penny Stocks

Markets

RDNT

DaVita Stock Gains 47.3% Year to Date: What's Behind the Rally?

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and maintains $9 price target.

HC Wainwright & Co. Reiterates Buy on Rockwell Medical, Maintains $9 Price Target

Rockwell Medical shares are trading higher after the company announced it secured a major deal to supply dialysis products for at-home and acute care.

Rockwell Medical (RMTI) announced that the company entered into a distribution agreement with Nephro Group Dialysis Centers, the largest dialysis p...

Rockwell Medical expands distribution in the Philippines

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Rockwell Med (RMTI – Research Report), reducing the price target to $7.00. Ram ...

Rockwell Medical: Resilient Growth Amidst Revenue Challenges and Strategic Diversification

Rockwell Medical (RMTI) announced that the company has partnered with HydroCare, a provider of state-of-the-art dialysis water treatment systems to...

Rockwell Medical partners with HydroCare

Rockwell Medical names new finance chief

Rockwell Medical (RMTI) announced that Jesse Neri was promoted to CFO. Neri joined Rockwell Medical in October 2023 as SVP, Finance to oversee all ...

Rockwell Medical names Jesse Neri as CFO

Rockwell Med ( ($RMTI) ) has issued an announcement. Rockwell Medical, Inc. announced the appointment of Jesse Neri as the Senior Vice President an...

Rockwell Med Appoints New CFO to Strengthen Leadership

Rockwell Medical (RMTI) entered into a product purchase agreement with the world's leading provider of dialysis products and services. Rockwell Med...

Rockwell Medical enters into multi-year product purchase agreement

Rockwell Medical sees over $10M net sales in 2025 from product purchase agreement

Rockwell Med (RMTI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C....

Strategic Partnerships and Revenue Growth Drive Buy Rating for Rockwell Medical

Top SA Quant-rated medical devices stocks as technicals look strong

AXGN

BFLY

CERS

CLPT

CNMD

DCTH

ECOR

EMBC

ENOV

GKOS

INGN

KRMD

LNSR

NPCE

PRCT

SIBN

SMTI

Press Releases

Rockwell Medical Named a Fortune 'Best Workplaces in Manufacturing & Production'

Rockwell Medical to Release Third Quarter 2024 Results on Monday, November 11, 2024

Rockwell Medical Announces Date Change for Third Quarter 2024 Earnings Conference Call and Webcast

Rockwell Medical Reports Third Quarter 2024 Earnings, Generates Profitability on a Cash Flow and Adjusted EBITDA Basis for the Second Consecutive Quarter

Rockwell Medical Expands Distribution in the Philippines

Rockwell Medical Partners with HydroCare to Distribute and Install its Dry Acid Concentrate Mix System

Rockwell Medical Promotes Jesse Neri to Chief Financial Officer

Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card

UPDATE: Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card

Rockwell Medical Enters into a Multi-Year Product Purchase Agreement with the World's Leading Provider of Dialysis Products and Services

Align Tech

Avanos Medical

Bioventus

Comments

Rockwell Medical

Rockwell Medical (RMTI) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル